Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination of amisulpride and dexamethasone**. Amisulpride is a *selective dopamine D2 and D3 receptor antagonist*, primarily classified as an atypical antipsychotic, also used intravenously as an antiemetic for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults. Its mechanism is based on preferential antagonism of D2 and D3 receptors, targeting symptoms of schizophrenia and preventing nausea/vomiting by blocking dopamine signaling in the chemoreceptor trigger zone. Dexamethasone is a *synthetic glucocorticoid corticosteroid* with potent anti-inflammatory and immunosuppressant properties, often used for its antiemetic effects in surgical and chemotherapy settings. Clinically, the combination is used for multimodal antiemetic prophylaxis in high-risk patients undergoing surgery under general anesthesia, leveraging their distinct mechanisms to provide enhanced prevention of PONV[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amisulpride + dexamethasone.